Business Segments Cytokinetics, Incorporated
Stocks
CYTK
US23282W6057
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.15 USD | +1.27% |
|
-1.86% | +10.40% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biotechnology | 70.43M | 94.59M | 7.53M | 18.47M | 88.04M | |||||
Total Assets | 841M | 1.01B | 824M | 1.4B | 1.42B | |||||
Interest Expense | -29.33M | -51.16M | -57.67M | -86.51M | -104M | |||||
CAPEX | -48.87M | -11.34M | -1.42M | -3.91M | -24.81M | |||||
EBT | -215M | -389M | -526M | -590M | -785M | |||||
D&A | 2.28M | 5.81M | 11.89M | 9.53M | 10.12M | |||||
Operating Income | -186M | -324M | -496M | -536M | -612M | |||||
Net Income | -215M | -389M | -526M | -590M | -785M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 70.43M | 94.59M | 7.53M | 18.47M | 88.04M | |||||
Total Assets | 841M | 1.01B | 824M | 1.4B | 1.42B | |||||
Interest Expense | -29.33M | -51.16M | -57.67M | -86.51M | -104M | |||||
D&A | 2.28M | 5.81M | 11.89M | 9.53M | 10.12M | |||||
CAPEX | -48.87M | -11.34M | -1.42M | -3.91M | -24.81M | |||||
Net Income | -215M | -389M | -526M | -590M | -785M | |||||
EBT | -215M | -389M | -526M | -590M | -785M | |||||
Operating Income | -186M | -324M | -496M | -536M | -612M |
- Stock Market
- Stocks
- CYTK Stock
- Financials Cytokinetics, Incorporated
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition